Subscribe To
Sutro biopharma: luvelta data for endometrial cancer treatment approaching
Sutro Biopharma is advancing its lead candidate, luvelta, for the treatment of various types of cancer,...
October 9, 2023, 9:48 am
Eu regulatory order for illumina to sell grail could come next week - ft
An order from EU competition regulators for Illumina to sell cancer detection test maker Grail could co...
October 9, 2023, 9:16 am
Bristol-myers squibb enhances oncology portfolio in deal worth up to $5.8bn
Bristol-Myers Squibb Co (NYSE:BMY) has unveiled plans to buy Mirati Therapeutics (NASDAQ:MRTX) in a deal that values the ...
October 9, 2023, 6:16 am
Exact sciences schedules third quarter 2023 earnings call
MADISON, Wis. , Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer...
October 9, 2023, 6:00 am
Exact sciences to present late-breaking data from pivotal blue-c study on next-generation cologuard at acg 2023
MADISON, Wis. , Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of canc...
October 9, 2023, 5:58 am
Bristol-myers squibb enahnces oncology portfolio in deal worth up to $5.8bn
Bristol-Myers Squibb Co (NYSE:BMY) has unveiled plans to buy Mirati Therapeutics (NASDAQ:MRTX) in a deal that values the ...
October 9, 2023, 3:21 am
Alx oncology: on right track with latest interim analysis of evorpacept
ALX Oncology reported positive interim results from its phase 2 study using its anti-CD47 drug for HER2-positive gastric/gastroesophageal junction
October 9, 2023, 12:38 am
Bristol myers squibb to acquire mirati therapeutics in deal worth up to $5.8 billion
The deal expands the pharmaceutical company's portfolio of cancer drugs....
October 8, 2023, 6:12 pm
Bristol-myers squibb to acquire mirati in a $4.8 billion deal
Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, ...
October 8, 2023, 5:56 pm
Which is the better cancer-testing healthcare stock: exact sciences or guardant health?
Exact Sciences and Guardant Health have both enjoyed triple-digit revenue growth over the past five years. Exact Sciences' shares are up more than 31%...
October 8, 2023, 7:30 am
Merck's (mrk) meets goal in muscle-invasive bladder cancer study
Data from a late-stage study shows that Merck's (MRK) Keytruda lowered the risk of disease recurrence or death when used after surgery in certain pati...
October 6, 2023, 1:32 pm
Mirati (mrtx) surges 45% as sanofi reportedly eyes buyout
A Bloomberg article suggests that pharma giant Sanofi (SNY) is exploring a potential acquisition deal for small ...
October 6, 2023, 12:47 pm
Amgen to continue to seek full approval of lumakras cancer drug after fda panel votes against it
Amgen Inc. said it would continue to work closely with the Food and Drug Administration to seek full approval for its Lumakras ...
October 6, 2023, 8:36 am
Umoja biopharma to present at the 2023 cell & gene meeting on the mesa
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) — Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for soli...
October 5, 2023, 6:30 pm
Us fda panel gives thumbs down on approval for amgen lung cancer drug
Advisers to the U.S. Food and Drug Administration on Thursday found that data from a late-stage trial was not reliable enough to support traditional a...
October 5, 2023, 2:49 pm
Be the match raises $1.1 million at annual gala
Funds raised support saving more lives through blood stem cell transplants MINNEAPOLIS, Oct. 05, 2023 (GLOBE NEWSWIRE) — On Saturday, September 30, ...
October 5, 2023, 1:18 pm
Nuvalent stock gains on lung cancer data, but i'd only buy on dip
Nuvalent, Inc. stock gained 36% and reached an all-time high of $58 per share yesterday, with a market cap valuation of $3.3bn. The biotech company is...
October 5, 2023, 11:00 am
Perimeter medical imaging ai advances to next stage of grant funding program
Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) announced that it has been shortlisted in a grant funding process sponsored by the Advanced Resea...
October 5, 2023, 9:09 am
Merck blockbuster shows promise in bladder cancer
Merck & Co Inc (NYSE:MRK) has announced promising results from its phase III clinical trial of its blockbuster ...
October 5, 2023, 8:43 am
Merck reports positive results in late-stage trial of keytruda as treatment for bladder cancer
Merck & Co. Inc. MRK, +0.39% said Thursday a late-stage trial of its cancer treatment Keytruda met its ...
October 5, 2023, 7:26 am